IMRX Stock Overview
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Immuneering Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.45 |
| 52 Week High | US$16.17 |
| 52 Week Low | US$3.74 |
| Beta | 0 |
| 1 Month Change | -8.25% |
| 3 Month Change | -67.87% |
| 1 Year Change | -55.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.5% | 0.8% | 2.8% |
| 1Y | -55.5% | 7.1% | -9.2% |
Return vs Industry: IMRX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: IMRX underperformed the US Market which returned -9.2% over the past year.
Price Volatility
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IMRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IMRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 74 | Ben Zeskind | https://immuneering.com |
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
Immuneering Corporation Fundamentals Summary
| IMRX fundamental statistics | |
|---|---|
| Market Cap | US$117.50m |
| Earnings (TTM) | -US$48.05m |
| Revenue (TTM) | US$506.09k |
232.2x
P/S Ratio-2.4x
P/E RatioIs IMRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMRX income statement (TTM) | |
|---|---|
| Revenue | US$506.09k |
| Cost of Revenue | US$364.34k |
| Gross Profit | US$141.75k |
| Other Expenses | US$48.19m |
| Earnings | -US$48.05m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.82 |
| Gross Margin | 28.01% |
| Net Profit Margin | -9,494.86% |
| Debt/Equity Ratio | 0% |
How did IMRX perform over the long term?
See historical performance and comparison